Solara Active Pharma Sciences Limited (NSE:SOLARA)
India · Delayed Price · Currency is INR 515.00
+7.00 (1.38%)
Jul 31, 2026, 3:29 PM IST
NSE:SOLARA Revenue
Solara Active Pharma Sciences had revenue of 3.82B INR in the quarter ending June 30, 2026, with 19.57% growth. This brings the company's revenue in the last twelve months to 14.31B, up 15.49% year-over-year. In the fiscal year ending March 31, 2026, Solara Active Pharma Sciences had annual revenue of 13.69B with 6.64% growth.
Revenue (ttm)
14.31B
Revenue Growth
+15.49%
P/S Ratio
1.73
Revenue / Employee
8.06M
Employees
1,775
Market Cap
24.74B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 13.69B | 852.20M | 6.64% |
| Mar 31, 2025 | 12.84B | -51.60M | -0.40% |
| Mar 31, 2024 | 12.89B | -1.55B | -10.73% |
| Mar 31, 2023 | 14.44B | 1.75B | 13.83% |
| Mar 31, 2022 | 12.68B | -3.49B | -21.56% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 18.73B |
| Aarti Pharmalabs | 18.19B |
| Innova Captab | 16.30B |
| Windlas Biotech | 9.04B |
| Orchid Pharma | 8.11B |
| RPG Life Sciences | 7.34B |
| Ind-Swift Laboratories | 6.41B |
| Sigachi Industries | 4.86B |
Solara Active Pharma Sciences News
- 3 months ago - Solara Active Pharma share price jumps over 4% after USFDA closes Puducherry facility inspection with VAI status - Business Upturn
- 9 months ago - Solara Active Pharma’s Mangalore facility clears US FDA inspection with VAI classification - Business Upturn
- 9 months ago - Solara Active Pharma shares slump nearly 9% today after reporting Q2 net loss - Business Upturn
- 1 year ago - Solara Active Pharma shares rise 4% after Ambernath facility clears USFDA inspection with zero observations - Business Upturn
- 1 year ago - Solara Active Pharma shares down 5% as Managing Director Poorvank Purohit resigns - Business Upturn
- 1 year ago - Solara Active Pharma Sciences announces demerger of CRAMS and Polymers business - Business Upturn
- 1 year ago - Solara Active Pharma Sciences Q3 FY25 Results: Revenue up 41.6% YoY to Rs 300.31 crore - Business Upturn